Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
13.64
+0.21 (1.53%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 36,830 employees as of December 31, 2024. The number of employees decreased by 1,021 or -2.70% compared to the previous year.
Employees
36,830
Change (1Y)
-1,021
Growth (1Y)
-2.70%
Revenue / Employee
$449,199
Profits / Employee
-$44,502
Market Cap
15.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
TEVA News
- 8 days ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 11 days ago - Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention - GlobeNewsWire
- 17 days ago - New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable - GlobeNewsWire
- 21 days ago - Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 - GlobeNewsWire
- 21 days ago - Teva Releases Q1 2025 Aide Memoire - GlobeNewsWire
- 4 weeks ago - Drugmakers agree to participate in second round of price negotiations - Reuters
- 5 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript) - Seeking Alpha